856867-55-5

Product Details

Appearance:powder

Throughput:100|Kilogram|Month

pd_productuse:intermediate

Delivery Time:in stock

Purity:99% purity

Boiling point     725.6±70.0 °C(Predicted)
density     1.75±0.1 g/cm3(Predicted)
storage temp.     Inert atmosphere,2-8°C
pka    1.81±0.10(Predicted)

A new antibacterial drug    Tedizolid phosphate is a new anti-bacterial drug developed by CUBIST PHARMS company. Tedizolid phosphate is a prodrug of Tedizolid. After oral or intravenous administration, Tedizolid phosphate is converted to Tedizolid by phosphatase. Tedizolid is the second generation of oxazolidinone antibiotics, a protein synthesis inhibitors. binding the 50S subunit of bacterial ribosomes, it can inhibit protein synthesis and play a role of antibacterial. It  is not easy to have  cross-resistance with other types of antibiotics, and has a longer half-life compared to linezolid.
On June 20, 2014, the US Food and Drug Administration (FDA) approved Tedizolid phosphate for use in certain sensitive bacterial-induced adult acute bacterial skin and skin structure infections (ABSSSI), with trade name SIVEXTRO, specification 200 mg. Tedizolid phosphate has been submitted a listing application in Europe and Canada currently, while the drug has not yet listed in China. Tedizolid's listing application is based on clinical trials ESTABLISH 1 and ESTABLISH 2. The results showed that Tedizolid achieved its primary endpoint and secondary endpoint in clinical trials of ABSSSI (defined by the FDA and the European Medicines Agency).
Clinical studies have shown that Tedizolid not only has a better clinical efficacy, and but shortened the treatment cycle by 40% compared with linezolid.
In addition, the study of Tedizolid for hospital acquired/ventilator-associated bacterial pneumonia (HABP/VABP) has entered the clinical phase II.
Analyst Larry Smith predicts the drug will sell more than $ 1 billion by 2020.
This information was edited by Xiao Nan from Chemicalbook (2015-08-14).